Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages 480-492

  Dagan, Ron ^a   Pelton, Stephen ^b   Bakaletz, Lauren ^c   Cohen, Robert ^d  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

BIOFILM; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; NONTYPEABLE HAEMOPHILUS INFLUENZAE; OTITIS MEDIA; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TISSUE INJURY; VACCINATION; ACUTE DISEASE; IMMUNOLOGY; PATHOGENICITY; PNEUMOCOCCAL INFECTIONS;

ACUTE DISEASE; DISEASE PROGRESSION; HUMANS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84962605640     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00549-6     Document Type: Review

References (141)

1. Leibovitz E, Greenberg D Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J 2004, 27:475-488.
2. Dagan R, Leibovitz E, Greenberg D, Bakaletz L, Givon-Lavi N Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. J Infect Dis 2013, 208:1152-1160.
3. Holder RC, Kirse DJ, Evans AK, et al. One third of middle ear effusions from children undergoing tympanostomy tube placement had multiple bacterial pathogens. BMC Pediatr 2012, 12:87.
4. Massa HM, Cripps AW, Lehmann D Otitis media: viruses, bacteria, biofilms and vaccines. Med J Aust 2009, 191(suppl):S44-S49.
5. Rovers MM, Schilder AG, Zielhuis GA, Rosenfeld RM Otitis media. Lancet 2004, 363:465-473.
6. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013, 131:e964-e999.
7. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis 2014, 14:205-212.
8. Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2013, 1. CD000219.
9. Brook I Watchful waiting versus immediate antibiotic treatment in the management of acute otitis media in children. Curr Infect Dis Rep 2007, 9:183-184.
10. Qureishi A, Lee Y, Belfield K, Birchall JP, Daniel M Update on otitis media-prevention and treatment. Infect Drug Resist 2014, 7:15-24.
11. Jung TT, Alper CM, Hellstrom SO, et al. Panel 8: Complications and sequelae. Otolaryngol Head Neck Surg 2013, 148(suppl):E122-E143.
12. Soni A Medical Expenditure Panel Survey (statistical brief #228): Ear infections (otitis media) in children (0-17): use and expenditures, 2006 2008, Agency for Healthcare Research and Quality, Rockville, MD, (accessed Jan 18, 2016). http://meps.ahrq.gov/mepsweb/data_files/publications/st228/stat228.pdf.
13. Monasta L, Ronfani L, Marchetti F, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One 2012, 7:e36226.
14. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012, 54:1765-1773.
15. Fletcher MA, Fritzell B Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol 2012, 2012:312935.
16. De Wals P, Erickson L, Poirier B, Pépin J, Pichichero ME How to compare the efficacy of conjugate vaccines to prevent acute otitis media?. Vaccine 2009, 27:2877-2883.
17. Barkai G, Leibovitz E, Givon-Lavi N, Dagan R Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009, 28:466-471.
18. Stol K, Verhaegh SJ, Graamans K, et al. Microbial profiling does not differentiate between childhood recurrent acute otitis media and chronic otitis media with effusion. Int J Pediatr Otorhinolaryngol 2013, 77:488-493.
19. Bingen E, Cohen R, Jourenkova N, Gehanno P Epidemiologic study of conjunctivitis-otitis syndrome. Pediatr Infect Dis J 2005, 24:731-732.
20. Caeymaex L, Varon E, Levy C, et al. Characteristics and outcomes of acute otitis media in children carrying Streptococcus pneumoniae or Haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014, 33:533-536.
21. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187-195. the Northern California Kaiser Permanente Vaccine Study Center Group.
22. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003, 22:10-16.
23. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409. the Finnish Otitis Media Study Group.
24. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J 2004, 23:732-738.
25. Sarasoja I, Jokinen J, Lahdenkari M, Kilpi T, Palmu AA Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J 2013, 32:517-520.
26. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118:865-873.
27. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007, 119:707-715.
28. Zhou F, Shefer A, Kong Y, Nuorti JP Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008, 121:253-260.
29. Jardine A, Menzies RI, Deeks SL, Patel MS, McIntyre PB The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009, 28:761-765.
30. Coticchia JM, Chen M, Sachdeva L, Mutchnick S New paradigms in the pathogenesis of otitis media in children. Front Pediatr 2013, 1:52.
31. Bluestone CD, Stephenson JS, Martin LM Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992, 11(suppl):S7-11.
32. Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010, 304:2161-2169.
33. Hanage WP Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol 2008, 3:23-30.
34. Fletcher MA, Fritzell B Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 2007, 25:2507-2512.
35. Pichichero ME Evolving shifts in otitis media pathogens: relevance to a managed care organization. Am J Manag Care 2005, 11(suppl):S192-S201.
36. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 2006, 117:1823-1829.
37. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007, 195:347-352.
38. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463. the Active Bacterial Core Surveillance of the Emerging Infections Program Network.
39. Weinberger DM, Malley R, Lipsitch M Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
40. Tan TQ Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012, 25:409-419.
41. Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011, 29:1959-1967.
42. Schuerman L, Borys D, Hoet B, Forsgren A, Prymula R Prevention of otitis media: now a reality?. Vaccine 2009, 27:5748-5754.
43. Cunningham M, Guardiani E, Kim HJ, Brook I Otitis media. Future Microbiol 2012, 7:733-753.
44. Wiertsema SP, Kirkham LA, Corscadden KJ, et al. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Vaccine 2011, 29:5163-5170.
45. Casey JR, Adlowitz DG, Pichichero ME New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010, 29:304-309.
46. Vergison A Microbiology of otitis media: a moving target. Vaccine 2008, 26(suppl 7):G5-10.
47. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004, 23:829-833.
48. McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2005, 40:1738-1744.
49. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009, 199:776-785.
50. Kilpi T, Herva E, Kaijalainen T, Syrjänen R, Takala AK Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001, 20:654-662.
51. Palmu AA, Herva E, Savolainen H, Karma P, Mäkelä PH, Kilpi TM Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis 2004, 38:234-242.
52. Rodriguez WJ, Schwartz RH Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J 1999, 18:942-944.
53. Polachek A, Greenberg D, Lavi-Givon N, et al. Relationship among peripheral leukocyte counts, etiologic agents and clinical manifestations in acute otitis media. Pediatr Infect Dis J 2004, 23:406-413.
54. Heikkinen T, Ghaffar F, Okorodudu AO, Chonmaitree T Serum interleukin-6 in bacterial and nonbacterial acute otitis media. Pediatrics 1998, 102:296-299.
55. Jaye DL, Waites KB Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997, 16:735-746.
56. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 2006, 25:602-607.
57. Alonso M, Marimon JM, Ercibengoa M, Pérez-Yarza EG, Pérez-Trallero E Dynamics of Streptococcus pneumoniae serotypes causing acute otitis media isolated from children with spontaneous middle-ear drainage over a 12-year period (1999-2010) in a region of northern Spain. PLoS One 2013, 8:e54333.
58. Leibovitz E, Satran R, Piglansky L, et al. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae?. Pediatr Infect Dis J 2003, 22:509-515.
59. Klein JO The burden of otitis media. Vaccine 2000, 19(suppl 1):S2-S8.
60. Daly KA, Brown JE, Lindgren BR, Meland MH, Le CT, Giebink GS Epidemiology of otitis media onset by six months of age. Pediatrics 1999, 103:1158-1166.
61. Gisselsson-Solén M, Henriksson G, Hermansson A, Melhus A Risk factors for carriage of AOM pathogens during the first 3 years of life in children with early onset of acute otitis media. Acta Otolaryngol 2014, 134:684-690.
62. de Hoog ML, Venekamp RP, van der Ent CK, et al. Impact of early daycare on healthcare resource use related to upper respiratory tract infections during childhood: prospective WHISTLER cohort study. BMC Med 2014, 12:107.
63. Murrah KA, Pang B, Richardson S, et al. Nonencapsulated Streptococcus pneumoniae causes otitis media during single-species infection and during polymicrobial infection with nontypeable Haemophilus influenzae. Pathog Dis 2015, 73:ftu011.
64. Juhn SK, Tsuprun V, Lee Y-W, Hunter B, Schachern P Interaction between middle and inner ears in otitis media. Audiol Med 2004, 3:158-161.
65. Armbruster CE, Hong W, Pang B, et al. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio 2010, 1:e00102-e00110.
66. Karevold G, Bentdal YE, Nafstad P, Kvaerner KJ Surgery for otitis media and infectious susceptibility in 10-year old school children. Int J Pediatr Otorhinolaryngol 2009, 73:603-606.
67. Teele DW, Klein JO, Rosner B Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989, 160:83-94.
68. Kuo CL, Lien CF, Chu CH, Shiao AS Otitis media with effusion in children with cleft lip and palate: a narrative review. Int J Pediatr Otorhinolaryngol 2013, 77:1403-1409.
69. Shapiro NL, Novelli V Otitis media in children with vertically-acquired HIV infection: the Great Ormond Street Hospital experience. Int J Pediatr Otorhinolaryngol 1998, 45:69-75.
70. Çağlar Ö, Bülbül F, Sennaroğlu L Incidence of otitis media with effusion and long-term clinical findings in children with cleft lip and palate types. Kulak Burun Bogaz Ihtis Derg 2013, 23:268-274.
71. Rovers M, Haggard M, Gannon M, Koeppen-Schomerus G, Plomin R Heritability of symptom domains in otitis media: a longitudinal study of 1,373 twin pairs. Am J Epidemiol 2002, 155:958-964.
72. Casselbrant ML, Mandel EM, Fall PA, et al. The heritability of otitis media: a twin and triplet study. JAMA 1999, 282:2125-2130.
73. Jones EA, Kananurak A, Bevins CL, Hollox EJ, Bakaletz LO Copy number variation of the beta defensin gene cluster on chromosome 8p influences the bacterial microbiota within the nasopharynx of otitis-prone children. PLoS One 2014, 9:e98269.
74. Bluestone CD Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998, 42:207-223.
75. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006, 296:202-211.
76. Hau I, Levy C, Caeymaex L, Cohen R Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs 2014, 16:1-12.
77. Thornton RB, Rigby PJ, Wiertsema SP, et al. Multi-species bacterial biofilm and intracellular infection in otitis media. BMC Pediatr 2011, 11:94.
78. Leibovitz E, Asher E, Piglansky L, et al. Is bilateral acute otitis media clinically different than unilateral acute otitis media?. Pediatr Infect Dis J 2007, 26:589-592.
79. Pumarola F, Marès J, Losada I, et al. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol 2013, 77:1231-1236.
80. Leach AJ, Morris PS The burden and outcome of respiratory tract infection in Australian and aboriginal children. Pediatr Infect Dis J 2007, 26(suppl):S4-S7.
81. Commisso R, Romero-Orellano F, Montanaro PB, Romero-Moroni F, Romero-Diaz R Acute otitis media: bacteriology and bacterial resistance in 205 pediatric patients. Int J Pediatr Otorhinolaryngol 2000, 56:23-31.
82. García-Cobos S, Moscoso M, Pumarola F, et al. Frequent carriage of resistance mechanisms to β-lactams and biofilm formation in Haemophilus influenzae causing treatment failure and recurrent otitis media in young children. J Antimicrob Chemother 2014, 69:2394-2399.
83. Mizrahi A, Cohen R, Varon E, et al. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis 2014, 14:400.
84. Marks LR, Mashburn-Warren L, Federle MJ, Hakansson AP Streptococcus pyogenes biofilm growth in vitro and in vivo and its role in colonization, virulence, and genetic exchange. J Infect Dis 2014, 210:25-34.
85. Langereis JD, Hermans PW Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett 2013, 346:81-89.
86. Potera C Forging a link between biofilms and disease. Science 1999, 283:1837-1839.
87. Stewart PS, Costerton JW Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358:135-138.
88. Jalalvand F, Riesbeck K Haemophilus influenzae: recent advances in the understanding of molecular pathogenesis and polymicrobial infections. Curr Opin Infect Dis 2014, 27:268-274.
89. Weimer KE, Armbruster CE, Juneau RA, Hong W, Pang B, Swords WE Coinfection with Haemophilus influenzae promotes pneumococcal biofilm formation during experimental otitis media and impedes the progression of pneumococcal disease. J Infect Dis 2010, 202:1068-1075.
90. Sjöström K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42:451-459.
91. Blanchette-Cain K, Hinojosa CA, Akula Suresh Babu R, et al. Streptococcus pneumoniae biofilm formation is strain dependent, multifactorial, and associated with reduced invasiveness and immunoreactivity during colonization. MBio 2013, 4:e00745-e00813.
92. Tapiainen T, Kujala T, Kaijalainen T, et al. Biofilm formation by Streptococcus pneumoniae isolates from paediatric patients. APMIS 2010, 118:255-260.
93. Camilli R, Pantosti A, Baldassarri L Contribution of serotype and genetic background to biofilm formation by Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2011, 30:97-102.
94. Cope EK, Goldstein-Daruech N, Kofonow JM, et al. Regulation of virulence gene expression resulting from Streptococcus pneumoniae and nontypeable Haemophilus influenzae interactions in chronic disease. PLoS One 2011, 6:e28523.
95. Allan RN, Skipp P, Jefferies J, et al. Pronounced metabolic changes in adaptation to biofilm growth by Streptococcus pneumoniae. PLoS One 2014, 9:e107015.
96. Bakaletz LO, Baker BD, Jurcisek JA, et al. Demonstration of Type IV pilus expression and a twitching phenotype by Haemophilus influenzae. Infect Immun 2005, 73:1635-1643.
97. Jurcisek JA, Bakaletz LO Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J Bacteriol 2007, 189:3868-3875.
98. Zuliani G, Carron M, Gurrola J, et al. Identification of adenoid biofilms in chronic rhinosinusitis. Int J Pediatr Otorhinolaryngol 2006, 70:1613-1617.
99. De Schutter I, De Wachter E, Crokaert F, et al. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: identification of nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis 2011, 52:1437-1444.
100. Chole RA, Faddis BT Evidence for microbial biofilms in cholesteatomas. Arch Otolaryngol Head Neck Surg 2002, 128:1129-1133.
101. Torretta S, Drago L, Marchisio P, et al. Recurrences in chronic tonsillitis substained by tonsillar biofilm-producing bacteria in children. Relationship with the grade of tonsillar hyperplasy. Int J Pediatr Otorhinolaryngol 2013, 77:200-204.
102. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006, 174:213-220.
103. Rose AS, Thorp BD, Zanation AM, Ebert CS Chronic rhinosinusitis in children. Pediatr Clin North Am 2013, 60:979-991.
104. Teeters J, Boles M, Ethier J, Jenkins A, Curtis LG Acute rhinosinusitis: new guidelines for diagnosis and treatment. JAAPA 2013, 26:57-59.
105. King P Haemophilus influenzae and the lung (Haemophilus and the lung). Clin Transl Med 2012, 1:10.
106. O'Grady KA, Grimwood K, Cripps A, et al. Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials 2013, 14:282.
107. Cullen L, McClean S Bacterial adaptation during chronic respiratory infections. Pathogens 2015, 4:66-89.
108. Biesbroek G, Tsivtsivadze E, Keijser BJF, et al. Dynamics of microbiota profiles dominated by Streptococcus pneumoniae over time. 9th International Symposium on Pneumococci and Pneumococcal Diseases; Hyderabad, India; March 9-13, 2014.
109. Biesbroek G, Wang X, Keijser BJ, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis 2014, 20:201-210.
110. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367:740-748.
111. O'Brien KL, David AB, Chandran A, et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr Infect Dis J 2008, 27:71-73.
112. Gisselsson-Solén M, Melhus A, Hermansson A Pneumococcal vaccination in children at risk of developing recurrent acute otitis media-a randomized study. Acta Paediatr 2011, 100:1354-1358.
113. Jokinen J, Palmu AA, Kilpi T Acute otitis media replacement and recurrence in the Finnish otitis media vaccine trial. Clin Infect Dis 2012, 55:1673-1676.
114. van Kempen MJ, Vermeiren JS, Vaneechoutte M, et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative?. Int J Pediatr Otorhinolaryngol 2006, 70:275-285.
115. Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003, 361:2189-2195.
116. van Heerbeek N, Straetemans M, Wiertsema SP, et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 2006, 117:603-608.
117. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001, 20:951-958.
118. Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003, 37:1155-1164. the Finnish Otitis Media Study Group.
119. Casey JR, Pichichero ME Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004, 23:824-828.
120. Brook I, Gober AE Bacteriology of spontaneously draining acute otitis media in children before and after the introduction of pneumococcal vaccination. Pediatr Infect Dis J 2009, 28:640-642.
121. Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25:1001-1007.
122. Dupont D, Mahjoub-Messai F, François M, et al. Evolving microbiology of complicated acute otitis media before and after introduction of the pneumococcal conjugate vaccine in France. Diagn Microbiol Infect Dis 2010, 68:89-92.
123. Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009, 28:e271-e275.
124. Durando P, Crovari P, Ansaldi F, et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009, 27:3459-3462. the Collaborative Group for Pneumococcal Vaccination in Liguria.
125. Stamboulidis K, Chatzaki D, Poulakou G, et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J 2011, 30:551-555.
126. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012, 31:297-301.
127. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis 2014, 59:1724-1732.
128. Mackenzie GA, Carapetis JR, Leach AJ, Morris PS Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. BMC Pediatr 2009, 9:14.
129. Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr 2014, 168:68-75.
130. Lau WC, Murray M, El-Turki A, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine 2015, 33:5072-5079.
131. Rodgers GL, Arguedas A, Cohen R, Dagan R Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 2009, 27:3802-3810.
132. Pichichero ME, Casey JR Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007, 298:1772-1778.
133. Porat N, Soley C, Marengolciene MM, et al. An international serotype 3 clone causing pediatric noninvasive infections in Israel, Costa Rica, and Lithuania. Pediatr Infect Dis J 2008, 27:709-712.
134. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO, Kaplan SL Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008, 122:34-39.
135. Ochoa-Gondar O, Figuerola-Massana E, Vila-Corcoles A, et al. Epidemiology of Streptococcus pneumoniae causing acute otitis media among children in Southern Catalonia throughout 2007-2013: incidence, serotype distribution and vaccine's effectiveness. Int J Pediatr Otorhinolaryngol 2015, 79:2104-2108. the EPIVAC Study Group.
136. Sartori AL, Minamisava R, Afonso ET, et al. Reduction in all-cause otits-related outpatient visits in children after PCV10 introduction in Brazil. 9th International Symposium on Pneumococci and Pneumococcal Diseases; Hyderabad, India; March 9-13, 2014.
137. Sigurdsson S, Kristinsson K, Erlendsdottir H, Hrafnkelsson B, Haraldsson A. An early reduction of acute otitis media and pneumonia in children in Iceland following PCV-10 immunization. 32nd Annual Meeting of the European Society for Paediatric Infectious Diseases; Dublin, Ireland; May 6-10, 2014.
138. Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014, 11:e1001657. the COMPAS Group.
139. Leach AJ, Wigger C, Hare K, et al. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr 2015, 15:162.
140. Dagan R, Ben-Shimol S, Leibovitz E, Givon-Lavi N. Implementation of PCV7/PCV13 in Israel had a significant impact on both pneumococcal and non-pneumococcal complex otitis media rates. IDWeek; Philadelphia, PA, USA; Oct 8-12, 2014.
141. Ben-Shimol S, Greenberg D, Leibovitz E, Givon-Lavi N, Dagan R. Near disappearance of antibiotic-resistant pneumococcal otitis media, associated with high PCV7/PCV13 uptake and substantial decrease of PCV13-serotypes nasophyaryngeal carriage. 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases; Leipzig, Germany; May 12-16, 2015.